Dupilumab De-escalation in Pediatric Atopic Dermatitis
Phase 4
30
about 3.1 years
1–17
1 site in MD
What this study is about
Researchers are testing whether children with atopic dermatitis can stop or reduce their dupilumab treatment if they have achieved good control of their skin condition. The trial will last for 1124 days and involve approximately 30 children aged 1 to 17 years.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Dupilumab - Discontinuation
- 2.Take Dupilumab - Dose Reduction
- 3.Take Dupilumab - Standard Dose
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Secondary: Adverse Events After Dupilumab Dose-reduction or Discontinuation, Change in Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety questionnaire score, Change in Patient-Reported Outcomes Measurement Information System (PROMIS) Cognitive Function questionnaire score, Change in Patient-Reported Outcomes Measurement Information System (PROMIS) Depressive Symptoms questionnaire score, Change in Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health questionnaire score, Change in Patient-Reported Outcomes Measurement Information System (PROMIS) Itch questionnaire score, Change in Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Intensity questionnaire score, Change in Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Problem questionnaire score
Dermatology